| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9911c1ab8f7dd4cfbb513021437ab171 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D295-155 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D295-155
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2010-09-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2015-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9049f61abb7e9f0b54bc1eccbc960e54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a475b08fbee318a63eda6b81d5bbf55b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0c9fab8063972875ecc96a7e14e9e5f4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_822744949b068a6339070b9048ebec34 |
| publicationDate |
2015-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
RU-2551376-C2 |
| titleOfInvention |
Abt-263 crystalline forms and solvates for treatment of bcl-2 protein related diseases |
| abstract |
FIELD: chemistry. n SUBSTANCE: invention relates to organic chemistry, specifically to N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-ene-1-yl)methyl)piperazine-1-yl)benzoyl)-4-(((1R)-3-(morpholine-4-yl)-1-((phenylsulphanyl)methyl)propyl)-amino)-3-((trifluoromethyl)sulphonyl)benzenesulphonamide (ABT-263) in a solid crystalline form. The invention also relates to a pharmaceutical composition on the basis of the above crystalline forms, suitable for the treatment of diseases, characterised by the apoptosis disorder and/or overexpression of one or more anti-apoptotic Bcl-2 family proteins. n EFFECT: obtained new crystalline forms of ABT-263 with useful biological properties. n 35 cl, 2 dwg, 22 tbl |
| priorityDate |
2009-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |